NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock Has Consensus Target Price of $49.00 According to Analysts

Key Points

• Analysts remain broadly positive: NewAmsterdam Pharma has a “Moderate Buy” consensus from 13 brokerages, with an average 12-month price target of $49.00 versus the stock’s $22.27 opening price.
• Recent financial results were mixed: The company reported a quarterly loss of $0.52 per share, missing estimates, while revenue of $3.70 million exceeded expectations. Analysts forecast a full-year loss of $1.82 per share.
• Ownership activity was notable: Institutional investors own 89.89% of the company, while insiders have sold 281,846 shares worth approximately $7.85 million over the past 90 days.

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the thirteen brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $49.00.

NAMS has been the topic of several recent research reports. BMO Capital Markets initiated coverage on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. They set an "outperform" rating and a $58.00 target price on the stock. Royal Bank Of Canada reduced their price objective on NewAmsterdam Pharma from $50.00 to $42.00 and set an "outperform" rating on the stock in a research note on Monday. HC Wainwright reissued a "buy" rating and set a $52.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, September 8th. Weiss Ratings restated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and issued a $45.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, July 20th.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $22.27 on Wednesday. The stock has a market capitalization of $2.66 billion, a PE ratio of -10.31 and a beta of 0.10. The company's fifty day moving average is $25.29 and its 200 day moving average is $30.13. NewAmsterdam Pharma has a fifty-two week low of $21.02 and a fifty-two week high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. The business had revenue of $3.70 million for the quarter, compared to the consensus estimate of $2.83 million. As a group, research analysts forecast that NewAmsterdam Pharma will post -1.82 earnings per share for the current year.

Insider Buying and Selling

In other NewAmsterdam Pharma news, insider Johannes Kastelein sold 50,246 shares of NewAmsterdam Pharma stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $25.03, for a total transaction of $1,257,657.38. Following the completion of the transaction, the insider directly owned 69,302 shares of the company's stock, valued at $1,734,629.06. The trade was a 42.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John W. Smither sold 1,600 shares of the business's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $25.32, for a total transaction of $40,512.00. Following the transaction, the director owned 8,760 shares in the company, valued at $221,803.20. This trade represents a 15.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 281,846 shares of company stock worth $7,847,619. 12.74% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Institutional investors have recently made changes to their positions in the company. KBC Group NV bought a new position in NewAmsterdam Pharma during the 1st quarter valued at about $37,000. AdvisorNet Financial Inc bought a new stake in NewAmsterdam Pharma in the first quarter worth about $82,000. Seven Fleet Capital Management LP bought a new stake in NewAmsterdam Pharma in the fourth quarter worth about $140,000. PNC Financial Services Group Inc. boosted its position in shares of NewAmsterdam Pharma by 147.7% during the first quarter. PNC Financial Services Group Inc. now owns 9,119 shares of the company's stock valued at $292,000 after buying an additional 5,437 shares during the period. Finally, AlphaCentric Advisors LLC boosted its position in shares of NewAmsterdam Pharma by 6.7% during the first quarter. AlphaCentric Advisors LLC now owns 14,656 shares of the company's stock valued at $469,000 after buying an additional 925 shares during the period. Institutional investors own 89.89% of the company's stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, with an emphasis on improving the treatment of dyslipidemia and reducing cardiovascular risk. The company's lead investigational product is obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor designed to lower low-density lipoprotein cholesterol and potentially address other lipid-related abnormalities.

Obicetrapib is being studied as an adjunct to existing lipid-lowering therapies, including in patients who have not achieved adequate cholesterol control and people with heterozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.